10x Genomics, Inc. ($TXG) Stock Forecast: Down 5.1% Today

What is 10x Genomics, Inc.?

10x Genomics (TXG) operates as a biotechnology company traded on the Nasdaq stock exchange, specializing in advanced solutions for analyzing biological systems at a single-cell level.

Why is 10x Genomics, Inc. going down?

TXG stock is down 5.1% on Jun 22, 2026 16:40

• The decline in TXG's stock today may be linked to a director, Shehnaaz Suliman, selling a significant amount of shares through open-market transactions, potentially indicating doubts about the company's future performance.
• Furthermore, the disclosure of Form 144 outlining planned sales of Class A Common stock associated with RSU vesting events is believed to have contributed to the negative market sentiment surrounding the company. Such actions by insiders might be perceived as them capitalizing on their holdings.
• The collective impact of these insider sales could have spurred additional selling pressure on TXG, driving down the stock price over the course of the trading session.
• Investors could interpret these insider transactions as a cautionary signal, leading them to reconsider their positions in 10x Genomics and influencing the bearish market trend witnessed today.

TXG Price Chart

TXG Technical Analysis

TXG News

10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades

10x Genomics, Inc. director Shehnaaz Suliman sold a total of 5,723 shares of Class A Common Stock in open-market transactions on June 16, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, at weighted average prices of $32.5890 and $33.2738 per share. Following these transactions, Suliman beneficially owns 32,086 shares of Class A Common Stock.

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-d2742e1c3306.html

TXG (Nasdaq) RSU vesting entries listed on Form 144 with JP Morgan intermediary

TXG (10x Genomics, Inc.) has filed a Form 144 notice detailing proposed sales of Class A Common stock related to multiple RSU vesting events, with JP Morgan Securities LLC identified as an intermediary. The filing specifies various vesting dates between August 2021 and August 2024, alongside the respective share counts. This notice is routine for RSU-related proposed sales and does not disclose sale prices, proceeds, or completion status.

https://www.stocktitan.net/sec-filings/TXG/144-10x-genomics-inc-sec-filing-fce261db42c2.html

Trending Today

10x Genomics, Inc. Price History

27.03.2026 - TXG Stock was up 5.2%

• The anticipation surrounding the upcoming virtual shareholder meeting and the disclosed information on director votes and executive compensation likely bolstered investor confidence, showcasing the company's commitment to transparency and strong governance.
• Positive financial outcomes for 2025, highlighted by increased revenue and gross margin, might have fueled investor optimism concerning the company's future growth prospects.
• The company's strategic approach to linking executive compensation with performance indicators such as total shareholder return and revenue growth underscores its dedication to enhancing shareholder value. This alignment potentially heightened investor confidence and contributed to the positive market momentum.

28.04.2026 - TXG Stock was up 10.1%

• Contributors to the stock's upward movement may include executives selling shares to cover tax obligations, a regular occurrence rather than a negative indicator.
• Positive developments like an "Outperform" rating from William Blair and a partnership with Bioptimus likely bolstered investor confidence.
• Despite potential market concerns from Microsoft’s GigaTIME and ARK Invest’s share sale, Stifel's maintained "Buy" rating and increased price target could have underpinned investors' belief in the long-term prospects of TXG, reinforcing the stock's bullish trend.

26.04.2026 - TXG Stock was up 5.8%

• Technical analyses and trading ideas for TXG show a bullish outlook, citing wave counts, ABC patterns, and indicators such as RSI and MACD.
• Traders are generally optimistic about TXG, proposing specific entry and exit points.
• The bullish momentum in TXG may stem from positive market sentiment towards the company's innovative genomics solutions and growth potential.

11.05.2026 - TXG Stock was down 5.0%

• Today's decline in TXG stock price could be linked to a sizable allocation of Restricted Stock Units (RSUs) granted to several directors. These RSUs, set to vest gradually, may have raised concerns among investors about potential dilution or future selling pressures.
• Ongoing issuance of RSUs to directors, with vesting schedules commencing in 2026, might have prompted shareholder apprehensions regarding the company's long-term strategy and its impact on stock valuation.
• Investors could be interpreting the RSU allocations as a sign of uncertainty or a lack of immediate positive drivers for the stock, contributing to a pessimistic market outlook.
• The market response may also be influenced by specific aspects of the RSU grants, such as the absence of cash outlay for the awards and the quarterly vesting format, potentially shaping perceptions of insider confidence and future stock performance.

15.05.2026 - TXG Stock was up 5.6%

• The positive movement in TXG stock today could be linked to the issuance of Restricted Stock Units (RSUs) to the company's directors.
• The RSUs, which are tied to continued service, serve as an incentive for directors to contribute to the company's progress and signify confidence in 10x Genomics' long-term outlook.
• The announcement of these equity awards may have boosted investor optimism, leading to increased buying activity and pushing the stock price up.
• In summary, the allocation of RSUs to key leadership demonstrates their commitment and likely played a role in today's positive market performance for TXG.

18.05.2026 - TXG Stock was up 6.7%

• The bullish movement in TXG today could be attributed to the filing of Form 144 detailing proposed sales of Class A Common stock related to RSU vesting events. This filing might have instilled confidence in investors about the company's growth prospects and financial stability.
• The involvement of JP Morgan Securities LLC as an intermediary in the proposed sales could have also positively influenced market sentiment towards TXG, as it signals interest from a reputable financial institution.
• Investors may interpret the routine nature of the Form 144 notice as a sign of transparency and adherence to regulatory requirements by TXG, further boosting confidence in the company's management practices and governance.
• Overall, the news of RSU vesting entries and the involvement of JP Morgan Securities LLC likely contributed to the bullish movement in TXG today, reflecting positive investor sentiment towards the company's future performance.

30.03.2026 - TXG Stock was up 5.0%

• The rise in TXG stock today may be linked to Vanguard's notable ownership in the company, as both Vanguard Capital Management and Vanguard Portfolio Management have disclosed substantial holdings. This vote of confidence from a major investment firm likely influenced investor sentiment positively.
• The announcement of an upcoming virtual shareholder meeting by 10X Genomics, highlighting strong financial performance and a commitment to linking executive compensation to company achievements, could also be a factor driving the bullish trend. Investors may interpret the company's transparent governance and robust financials as signals of potential future growth.
• The combination of Vanguard's increased ownership and the promising insights shared in the shareholder meeting may have bolstered investor confidence, leading to the upward movement in TXG stock.

29.03.2026 - TXG Stock was down 5.2%

• The bearish movement in TXG stock today could be attributed to Vanguard Portfolio Management's disclosure of holding over 6.9 million shares of the company, which may have raised concerns among investors about potential selling pressure.
• Additionally, the upcoming virtual shareholder meeting where executive compensation, director votes, and other key decisions will be discussed might have created uncertainty in the market, leading to a negative sentiment towards the stock.
• Despite the company's strong financial performance in 2025, including impressive revenue and cash reserves, the focus on executive compensation and corporate governance issues may have overshadowed these positive aspects, contributing to the bearish trend in TXG stock.

22.05.2026 - TXG Stock was down 5.1%

• The decline in TXG's stock today may be linked to a director, Shehnaaz Suliman, selling a significant amount of shares through open-market transactions, potentially indicating doubts about the company's future performance.
• Furthermore, the disclosure of Form 144 outlining planned sales of Class A Common stock associated with RSU vesting events is believed to have contributed to the negative market sentiment surrounding the company. Such actions by insiders might be perceived as them capitalizing on their holdings.
• The collective impact of these insider sales could have spurred additional selling pressure on TXG, driving down the stock price over the course of the trading session.
• Investors could interpret these insider transactions as a cautionary signal, leading them to reconsider their positions in 10x Genomics and influencing the bearish market trend witnessed today.

14.04.2026 - TXG Stock was up 5.1%

• The strong bullish movement in TXG's stock today can be attributed to the company's impressive performance in Q1 2026, despite a slight decrease in revenues.
• The boost in margins on consumables growth, along with a significant reduction in operating expenses and improved gross margins, likely instilled confidence in investors, driving the stock price up.
• Investors seem to be optimistic about TXG's ability to navigate challenges such as the absence of one-time revenues and focus on sustainable growth through core products and services.
• Overall, the market's positive reaction to TXG's financial results reflects a vote of confidence in the company's strategic initiatives and potential for future growth.

19.04.2026 - TXG Stock was up 5.3%

• The bullish movement in TXG's stock today could be attributed to positive factors such as the company's financial metrics, growth prospects, or upcoming events.
• The strong performance may also be a result of the market reacting positively to detected severe warning signs potentially indicating that the company is addressing any underlying issues effectively.
• Investors might be optimistic about TXG's future based on recent press releases and news headlines, leading to increased buying activity and driving the stock price higher.

01.05.2026 - TXG Stock was up 5.5%

• The rise in TXG's stock price today is linked to insider sales by key executives, such as the President, CFO, and CEO, aimed at meeting tax obligations. This selling activity may have boosted investor confidence, signaling insider belief in the stock's current value.
• Market reactions to concerns about the stock possibly being overvalued compared to its Fair Value were positive following the insider sales. Investors may have viewed these sales as routine compensation actions, rather than a lack of confidence in the company's future prospects.
• Positive recent analyst ratings, collaborations, and increased price targets could have also contributed to the optimistic sentiment surrounding TXG, eclipsing any doubts arising from the insider sales.
• In sum, the confluence of positive company developments and insider sales for tax obligations likely drove the upward movement in TXG's stock price today, reflecting a nuanced interplay between investor trust and market dynamics.